NCT06439485View on ClinicalTrials.gov

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

February 22, 2028

Study Completion Date

February 22, 2030

Conditions
Advanced CholangiocarcinomaFGFR2 Fusion
Interventions
DRUG

Pemigatinib

Given by PO

DRUG

Atezolizumab

Given by PO and IV

DRUG

Bevacizumab

Given by PO and IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER